Alitretinoin abrogates innate inflammation in palmoplantar pustular psoriasis

British Journal of Dermatology

Volumn 167, Issue 5, 2012, Pages 1170-1174

  Irla, N ^a   Navarini, A A ^b   Yawalkar, N ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; ANTIGEN; CD3 ANTIGEN; CD303 ANTIGEN; CD4 ANTIGEN; CD68 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; GLYCOPROTEIN P 15095; HLA DR ANTIGEN; LEUKOCYTE ELASTASE; T6 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DENDRITIC CELL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; INFLAMMATION; INFLAMMATORY INFILTRATE; INNATE IMMUNITY; MACROPHAGE; MALE; NEUTROPHIL; PAIN ASSESSMENT; PALMOPLANTAR PUSTULAR PSORIASIS; PALMOPLANTAR PUSTULAR PSORIASIS AREA AND SEVERITY INDEX; PRIORITY JOURNAL; PUSTULAR PSORIASIS; RATING SCALE; SKIN BIOPSY; TREATMENT DURATION; VISUAL ANALOG SCALE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PSORIASIS; TREATMENT OUTCOME; TRETINOIN; YOUNG ADULT;

EID: 84868206493     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11063.x     Document Type: Article

References (17)

1. Mrowietz U, van de Kerkhof PC,. Management of palmoplantar pustulosis: do we need to change? Br J Dermatol 2011; 164: 942-6.
2. Chalmers R, Hollis S, Leonardi-Bee J, et al. Interventions for chronic palmoplantar pustulosis. Cochrane Library 2009; 4: 1-49.
3. Ruzicka T, Lynde CW, Jemec GB, et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol 2008; 158: 808-17.
4. Hassan AS, Kaelin U, Braathen LR, Yawalkar N,. Clinical and immunopathologic findings during treatment of recalcitrant atopic eczema with efalizumab. J Am Acad Dermatol 2007; 56: 217-21.
5. Schlapbach C, Ochsenbein A, Kaelin U, et al. High numbers of DC-SIGN+ dendritic cells in lesional skin of cutaneous T-cell lymphoma. J Am Acad Dermatol 2010; 62: 995-1004.
6. Gibbs S, Backendorf C, Ponec M,. Regulation of keratinocyte proliferation and differentiation by all-trans-retinoic acid, 9-cis-retinoic acid and 1,25-dihydroxy vitamin D3. Arch Dermatol Res 1996; 288: 729-38.
7. Sørensen S, Sølvsten H, Politi Y, Kragballe K,. Effects of vitamin D3 on keratinocyte proliferation and differentiation in vitro: modulation by ligands for retinoic acid and retinoid X receptors. Skin Pharmacol 1997; 10: 144-52.
8. Xiao R, Kanekura T, Yoshida N, et al. 9-Cis-retinoic acid exhibits antifibrotic activity via the induction of cyclooxygenase-2 expression and prostaglandin E2 production in scleroderma fibroblasts. Clin Exp Dermatol 2008; 33: 484-90.
9. Ko J, Yun CY, Lee JS, et al. Differential regulation of CC chemokine receptors by 9-cis retinoic acid in the human mast cell line, HMC-1. Life Sci 2006; 79: 1293-300.
10. Zapata-Gonzalez F, Rueda F, Petriz J, et al. 9-cis-Retinoic acid (9cRA), a retinoid X receptor (RXR) ligand, exerts immunosuppressive effects on dendritic cells by RXR-dependent activation: inhibition of peroxisome proliferator-activated receptor gamma blocks some of the 9cRA activities, and precludes them to mature phenotype development. J Immunol 2007; 178: 6130-9.
11. Dawson HD, Collins G, Pyle R, et al. Direct and indirect effects of retinoic acid on human Th2 cytokine and chemokine expression by human T lymphocytes. BMC Immunol 2006; 7: 27.
12. Villablanca EJ, Zhou D, Valentinis B, et al. Selected natural and synthetic retinoids impair CCR7- and CXCR4-dependent cell migration in vitro and in vivo. J Leukoc Biol 2008; 84: 871-9.
13. Werner B, Bresch M, Brenner FM, Lima HC, et al. Comparative study of histopathological and immunohistochemical findings in skin biopsies from patients with psoriasis before and after treatment with acitretin. J Cutan Pathol 2008; 35: 302-10.
14. Gordon KB, Bonish BK, Patel T, et al. Br J Dermatol 2005; 153: 945-53.
15. Cumberbatch M, Bhushan M, Dearman RJ, et al. IL-1beta-induced Langerhans' cell migration and TNF-alpha production in human skin: regulation by lactoferrin. Clin Exp Immunol 2003; 132: 352-9.
16. Shklovskaya E, O'Sullivan BJ, Ng LG, et al. Langerhans cells are precommitted to immune tolerance induction. Proc Natl Acad Sci USA 2011; 108: 18049-54.
17. Yang Y, Merćep M, Ware CF, Ashwell JD,. Fas and activation-induced Fas ligand mediate apoptosis of T cell hybridomas: inhibition of Fas ligand expression by retinoic acid and glucocorticoids. J Exp Med 1995; 181: 1673-82.